Amryt Pharma unveils brand name for phase III cream for rare genetic skin disease

Amryt Pharma PLC (LON:AMYT) has taken another important step towards the global launch of its phase III treatment for the rare skin condition epidermolysis bullosa (EB) by announcing its brand name.

AP101 will be launched commercially as FILSUVEZ.

“This, alongside our recent completion of recruitment into the EASE study, represents further progress as we endeavour to develop a therapy for patients with EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment," said chief executive, Dr Joe Wiley.

The top-line read-out from phase III EASE clinical trial is expected towards the end of the third quarter, or early Q4, Amryt has previously guided.

EB is a painful condition where Read More – Source

Related Articles

Back to top button